192 related articles for article (PubMed ID: 7689035)
1. Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens.
Denton G; Sekowski M; Price MR
Cancer Lett; 1993 Jul; 70(3):143-50. PubMed ID: 7689035
[TBL] [Abstract][Full Text] [Related]
2. Peptide epitopes in breast cancer mucins.
Xing PX; Apostolopoulos V; Trapani J; Prenzoska J; McKenzie IF
Adv Exp Med Biol; 1994; 353():9-16. PubMed ID: 7527180
[No Abstract] [Full Text] [Related]
3. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
[TBL] [Abstract][Full Text] [Related]
4. Development of an anti-idiotypic antibody reactive with an antibody defining the epitope RPAP in the MUC-1 epithelial mucin core.
Bashford JL; Robins RA; Price MR
Int J Cancer; 1993 Jul; 54(5):778-83. PubMed ID: 7686886
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
[TBL] [Abstract][Full Text] [Related]
6. Sequential order of T and B cell epitopes affects immunogenicity but not antibody recognition of the B cell epitope.
Denton G; Hudecz F; Kajtár J; Murray A; Tendler SJ; Price MR
Pept Res; 1994; 7(5):258-64. PubMed ID: 7531518
[TBL] [Abstract][Full Text] [Related]
7. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
[TBL] [Abstract][Full Text] [Related]
8. Humanization of an anti-mucin antibody for breast and ovarian cancer therapy.
Baker TS; Bose CC; Caskey-Finney HM; King DJ; Lawson AD; Lyons A; Mountain A; Owens RJ; Rolfe MR; Sehdev M
Adv Exp Med Biol; 1994; 353():61-82. PubMed ID: 7985543
[TBL] [Abstract][Full Text] [Related]
9. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
Apostolopoulos V; Xing PX; McKenzie IF
Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
[TBL] [Abstract][Full Text] [Related]
10. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein.
Apostolopoulos V; Xing PX; Trapani JA; McKenzie IF
Br J Cancer; 1993 Apr; 67(4):713-20. PubMed ID: 7682431
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.
Gückel B; Rentzsch C; Nastke MD; Marmé A; Gruber I; Stevanović S; Kayser S; Wallwiener D
J Cancer Res Clin Oncol; 2006 Apr; 132(4):265-74. PubMed ID: 16374613
[TBL] [Abstract][Full Text] [Related]
12. Characterization of monoclonal antibody 436 recognizing the Arg-Pro-Ala-Pro sequence of the polymorphic epithelial mucin (PEM) protein core in breast carcinoma cells.
Nuti M; Turchi V; Rughetti A; Viacava P; Masci AM; Castagna M; Frati L
Int J Biol Markers; 1992; 7(2):71-9. PubMed ID: 1378874
[TBL] [Abstract][Full Text] [Related]
13. Does pregnancy immunize against breast cancer?
Agrawal B; Reddish MA; Krantz MJ; Longenecker BM
Cancer Res; 1995 Jun; 55(11):2257-61. PubMed ID: 7538899
[TBL] [Abstract][Full Text] [Related]
14. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
[TBL] [Abstract][Full Text] [Related]
15. Human B-cell immune response to the polymorphic epithelial mucin.
Rughetti A; Turchi V; Ghetti CA; Scambia G; Panici PB; Roncucci G; Mancuso S; Frati L; Nuti M
Cancer Res; 1993 Jun; 53(11):2457-9. PubMed ID: 8495404
[TBL] [Abstract][Full Text] [Related]
16. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
[TBL] [Abstract][Full Text] [Related]
17. Immune recognition of human colonic-tumour-associated MUC-2 mucins using an anti-peptide antibody.
Price MR; Sekowski M; Ladányi A; Uray K; Ma Y; Durrant L; Tendler SJ
Int J Cancer; 1993 Nov; 55(5):753-9. PubMed ID: 7503958
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
[TBL] [Abstract][Full Text] [Related]
19. Recognition of peptidyl epitopes by polymorphic epithelial mucin (PEM)-specific monoclonal antibodies.
Dion AS; Smorodinsky NI; Williams CJ; Wreschner DH; Major PP; Keydar I
Hybridoma; 1991 Oct; 10(5):595-610. PubMed ID: 1804772
[TBL] [Abstract][Full Text] [Related]
20. The immunogenicity of MUC1 peptides and fusion protein.
Apostolopoulos V; Pietersz GA; Xing PX; Lees CJ; Michael M; Bishop J; McKenzie IF
Cancer Lett; 1995 Mar; 90(1):21-6. PubMed ID: 7720038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
